Loading docket data…
What FDA may be missing
Themes that appear across multiple questions and multiple stakeholder groups, but that the discussion paper does not ask about directly. Each is drawn from the comments below it, not from the paper.
26 questions. See what stakeholders are telling FDA — and where the real disagreements are.
FDA released its discussion paper on generative AI-enabled medical devices on August 18, 2026. This tracker reads every public submission to the docket, maps each position to the question it answers, and keeps the source excerpt attached to the claim.
Loading docket data…
Themes that appear across multiple questions and multiple stakeholder groups, but that the discussion paper does not ask about directly. Each is drawn from the comments below it, not from the paper.
Comments are pulled from the public Regulations.gov docket. AI is used to segment submissions, map passages to the FDA questions they address, classify the position being expressed, and summarize that position in neutral language.
The tracker preserves distinctions among support, support with modification, opposition, mixed positions, and unclear positions rather than reducing comments to simple sentiment.
Every interpretation remains linked to the source passage and original submission so readers can inspect the evidence directly.
Vahana Labs’ editorial analysis, including commercialization and real-world deployment implications, is visually separated from what commenters themselves said.
Classifications and summaries are interpretive. The underlying public submission is authoritative.
Any position on this page opens to the passage it came from, the question it was mapped to, and the original submission. Read the source before relying on the summary.
Vahana read panels are interpretation, including commercialization and deployment consequences. They are never presented as a commenter position.